In accordance with the FSA's Disclosure and Transparency Rule 5.6.1, Proteome Sciences plc (the "Company") announces that the Company's issued share capital consists of 192,498,477 ordinary shares of 1 pence each ("Ordinary Shares") with voting rights. There are no Ordinary Shares held in treasury.
Therefore the total number of voting rights in Proteome Sciences plc at the date of this notice is 192,498,477. Read More
Proteome Sciences plc, a global leader in protein biomarkers has today granted a non-exclusive license to Randox Laboratories (“Randox”) of Crumlin, UK for its portfolio of stroke biomarkers. Read More.
Proteome Sciences plc Block Admission Report. Read More
28 March 2012, London, UK - Proteome Sciences, in collaboration with the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health and Merck Millipore, today announces the completion of the large, 1,000 sample Alzheimer’s Disease (AD) biomarker validation study. Preliminary results indicate that these biomarkers have significant potential diagnostic and prognostic utility that could form the basis of a series of simple blood tests for the diagnosis and management of this debilitating disease. Read More.
19th March 2012 Proteome Sciences plc (“Proteome Sciences”) announces that Euro-HYP-1, a consortium of leading academic, clinical and industrial European partners in which it is a member, has been awarded a near €11m grant under the EU Framework 7 programme for new ground breaking research on the treatment of stroke. Read More
The Company has been informed that Cubana Investments Limited (“Cubana”) has been acquired by Vulpes Life Science Fund (“Vulpes). Following this transaction, and as of 9 March 2012, Cubana no longer has a voting interest in the Company and Vulpes has voting control over 33,100,000 ordinary shares in the Company representing 17.19% of the Company’s voting share capital. Read More
The Company announces the appointment of Cenkos Securities plc, as Nominated Adviser and Broker to the Company, with immediate effect. Read More
Proteome Sciences plc (“Proteome”) announces that on 24 February 2012 it made an award of options over 328,105 Ordinary Shares of 1 pence each with an exercise price of 1 pence per share to Christopher Pearce, Chief Executive Officer under the 2011 Long Term Incentive Plan (the “LTIP”) . Read More
Proteome Sciences plc (the “Company”) announces that the Company’s issued share capital consists of 192,448,477 ordinary shares of 1 pence each (“Ordinary Shares”) with voting rights. There are no Ordinary Shares held in treasury. Read More
Proteome Sciences announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 176,069 ordinary shares of 1p each (the "New Ordinary Shares"). Read More
Further to comments in the Interim Statement of 30th September, 2011 regarding CK1δ (the candidate drug target for Alzheimer’s Disease), Proteome Sciences is pleased to announce that selected compounds, previously identified as potential inhibitors against CK1δ, have now been tested in cells and have shown strong activity. Further IP has been filed to cover the results which the Directors believe will considerably increase the value of the CK1δ programme. Read More
Proteome Sciences today announces that it has developed a number of novel invitro tests for chemical compounds and substances that induce allergies when they come into contact with the skin or the respiratory system. Testing for these allergens in products including chemicals, pharmaceuticals, cosmetics and detergents will become mandatory under EU legislation. Read more
November 2011 Proteome Sciences plc (“Proteome”) is pleased to announce that on 7 November it granted options under its 2011 Long Term Incentive Plan to certain directors. Read more.
Proteome Sciences plc block admission return. Read more
PS Announces half yearly statement. Read More
Proteome Sciences plc (“Proteome”) is pleased to announce that it has entered into a Master Research Agreement (MRA) with Siena Biotech S.p.A. (“Siena Biotech”) under which it has been retained as preferred supplier of protein and peptide biomarker services for Siena’s drug development programs. Read More
Proteome Sciences is pleased to announce the appointment of Glenn Barney as VP Business Development in North America. He brings over 25 years of experience with global pharmaceutical companies and the life science industry with extensive operations and business development expertise including building and managing global sales, service and product support teams and overseeing multiple product launches. Read More
Proteome Sciences plc (“Proteome”) a global leader in biomarkers will collaborate with Buck Institute for Research on Aging (“Buck”) to develop personalized molecular tests for estrogen receptor alpha (ERa) aimed at improving outcomes in breast cancer. Read More
Proteome Sciences plc (“Proteome”) a global leader in applied proteomics has entered into a collaboration agreement with Moffitt Cancer Center (“Moffitt”). Under the agreement, Proteome will support research to develop mass spectrometry assays measuring certain key signalling and repair pathway proteins that can be adapted for tumour biopsy analysis in the clinic. Read More
Proteome Sciences plc (“Proteome Sciences”) announces that it is a participant in a new project, that has been awarded a €6.99m EU Framework 7 Grant over the next two years to study the effects of environmental contamination in health and developmental disorders in children. Proteome Sciences will receive €530,058 for its contribution to the project. Read More
With the already considerable and growing portfolio of highly developed biomarkers, biomarker assays and the state of the art protein biomarker CRO capability Proteome Sciences now has under its belt, combined with a major increase in marketing and business development, the Board is most confident of achieving significant growth in revenues in the year ahead and beyond. Read More
Proteome Sciences plc (“Proteome”) is pleased to announce that Takeda Pharmaceutical Company Limited (“Takeda”) has signed a further contract to use PS Biomarker Services™. PS Biomarker Services™ will provide Takeda with mass spectrometric assays for disease related proteins. Read More
